Cyllene Therapeutics, formerly known as EG 427, today announced the successful closing of a €33 million Series C financing led by new investors GordonMD Global Investments® LP (“GordonMD”) and M Ventures. Existing investors including Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P. and Lamond Ventures LLC also participated in the round.
The proceeds will be used to support the continued clinical development of EG110A, the company’s lead precision genetic medicine candidate for severe chronic indications in neuro-urology, starting with neurogenic detrusor overactivity (NDO), as well as expansion of its HERMES non-replicating HSV-1 platform.
This financing marks a defining moment for our company as we continue advancing EG110A toward later-stage clinical development and in expanded indications, as well as broadening our pipeline of drug candidates emerging from our HERMES platform.Early clinical data generated to date with EG110A support our belief that localized, targeted DNA medicines can deliver durable efficacy with a strong safety profile in chronic neurological diseases. This financing will help us move further towards delivering this approach to more patients.
Reflecting its growth into a late-stage clinical biotech with global footprint, the company has rebranded from EG 427 to Cyllene Therapeutics (“Cyllene Tx”). The new name references Mount Cyllene, the mythical birthplace of Hermes, and honors the company’s HERMES technology, designed for safe and targeted delivery of therapeutic DNA
Cyllene Tx exemplifies the kind of bold, science-driven innovation for high unmet medical needs we seek to support at M Ventures. The HERMES platform represents a fundamentally differentiated approach to genetic medicine — one with the potential to address multiple high-burden neurological diseases with precision and durability. We are delighted to co-lead this financing alongside GordonMD and to partner with the Cyllene Tx team as they advance EG110A toward pivotal clinical milestones”
In ongoing clinical studies, EG110A continues to demonstrate encouraging efficacy and safety results in patients with neurogenic detrusor overactivity associated with spinal cord injury. Recent clinical data have shown substantial and sustained reductions in urinary incontinence episodes 9 months post treatment, providing early validation for the therapy’s potential to meaningfully improve patients’ daily lives. The findings also validate the company’s approach of selectively targeting type C sensory neurons to address the underlying drivers of bladder overactivity.
The preliminary clinical results of EG110A support the application of precision therapeutics within neuro-urology. With this funding, the company is positioned for global expansion, extending its pipeline into major neurological indications, including pain and migraine.
Cyllene Tx plans to initiate a Phase 2b/3 study with EG110A in 2027 to further evaluate dosing, safety, efficacy and durability, while very long-term efficacy will be further monitored in a separate observational study up to 5 years. In parallel, Cyllene Tx will expand into additional indications for EG110A, including overactive bladder.
